Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-003 · Medication safety
MED-RASI-001: RAS inhibitor post-initiation monitoring
RAS inhibitor post-initiation monitoring. Evaluates ACEi or ARB initiated or dose increased is true.
Condition
- All of:
- ACEi or ARB initiated or dose increased == true
What it reports
- Monitoring flag: check_BP_creatinine_potassium_in_2_to_4_weeks
- Message: Monitor BP, serum creatinine and potassium within 2-4 weeks after initiation or dose increase.
Evidence
- R1KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.Supports: CKD definition and chronicity CGA classification albuminuria confirmation risk prediction referral medication stewardship progression monitoring
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.